Endologix Inc fka ELGXQ

[TRIXXX]

Conference call highlights.
-42% global revenue growth
-first full quarter of positive cash flow
-first full six months of positive cash flow
-good position to expand in the aortic stent graft market
-sales force expanding and taking market share
-still plenty of opportunity for further growth
-2010 international market will be expanded into
-record revenue 13.2m in quarter
-gross margin improvements from volume efficiencies
-increase in cash balance
-raised revenue guidance
-IntuiTrac has an advantage in ease of use and expansion with new physicians
-competitors are Medtronic, W. L. Gore & Associates and Cook Group Inc.-but their devices are bigger and the smaller device of endologix has an advantage
-8% yearly procedure growth
All great news.